These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 16884295)

  • 1. Structure-activity relationships of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5' '-(4' '-amino-1' ',2' '-oxathiole-2' ',2' '-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization.
    Sluis-Cremer N; Hamamouch N; San Félix A; Velazquez S; Balzarini J; Camarasa MJ
    J Med Chem; 2006 Aug; 49(16):4834-41. PubMed ID: 16884295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2" -dioxide) derivatives with anti-HIV-1 and anti-human-cytomegalovirus activity.
    de Castro S; Lobatón E; Pérez-Pérez MJ; San-Félix A; Cordeiro A; Andrei G; Snoeck R; De Clercq E; Balzarini J; Camarasa MJ; Velázquez S
    J Med Chem; 2005 Feb; 48(4):1158-68. PubMed ID: 15715482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position.
    Bonache MC; Chamorro C; Velázquez S; De Clercq E; Balzarini J; Barrios FR; Gago F; Camarasa MJ; San-Félix A
    J Med Chem; 2005 Oct; 48(21):6653-60. PubMed ID: 16220981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abasic analogues of TSAO-T as the first sugar derivatives that specifically inhibit HIV-1 reverse transcriptase.
    Velázquez S; Chamorro C; Pérez-Pérez MJ; Alvarez R; Jimeno ML; Martín-Domenech A; Pérez C; Gago F; De Clercq E; Balzarini J; San-Félix A; Camarasa MJ
    J Med Chem; 1998 Nov; 41(23):4636-47. PubMed ID: 9804703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus type 1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"- oxathiole-2",2"-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analogues.
    Balzarini J; Velazquez S; San-Felix A; Karlsson A; Perez-Perez MJ; Camarasa MJ; De Clercq E
    Mol Pharmacol; 1993 Jan; 43(1):109-14. PubMed ID: 7678689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase.
    Rodríguez-Barrios F; Pérez C; Lobatón E; Velázquez S; Chamorro C; San-Félix A; Pérez-Pérez MJ; Camarasa MJ; Pelemans H; Balzarini J; Gago F
    J Med Chem; 2001 Jun; 44(12):1853-65. PubMed ID: 11384232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
    Arion D; Fletcher RS; Borkow G; Camarasa MJ; Balzarini J; Dmitrienko GI; Parniak MA
    Mol Pharmacol; 1996 Nov; 50(5):1057-64. PubMed ID: 8913335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational analysis of aza analogues of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranose]-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide) (TSAO) as HIV-1 reverse transcriptase inhibitors: relevance of conformational properties on the inhibitory activity.
    Soriano E; Marco-Contelles J; Tomassi C; Nguyen Van Nhien A; Postel D
    J Chem Inf Model; 2006; 46(4):1666-77. PubMed ID: 16859298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole 2",2"-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity.
    Alvarez R; Velázquez S; San-Félix A; Aquaro S; De Clercq E; Perno CF; Karlsson A; Balzarini J; Camarasa MJ
    J Med Chem; 1994 Nov; 37(24):4185-94. PubMed ID: 7527463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An approach towards the synthesis of potential metal-chelating TSAO-T derivatives as bidentate inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
    Chamorro C; Camarasa MJ; Pérez-Pérez MJ; de Clercq E; Balzarini J; San Félix A
    Antivir Chem Chemother; 1998 Sep; 9(5):413-22. PubMed ID: 9875394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of TSAO derivatives with an unusual HIV-1 activity/resistance profile.
    de Castro S; García-Aparicio C; Van Laethem K; Gago F; Lobatón E; De Clercq E; Balzarini J; Camarasa MJ; Velázquez S
    Antiviral Res; 2006 Aug; 71(1):15-23. PubMed ID: 16616962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regiospecific synthesis and anti-human immunodeficiency virus activity of novel 5-substituted N-alkylcarbamoyl and N,N-dialkylcarbamoyl 1,2,3-triazole-TSAO analogues.
    Velázquez S; Alvarez R; Pérez C; Gago F; De Clercq E; Balzarini J; Camarasa MJ
    Antivir Chem Chemother; 1998 Nov; 9(6):481-9. PubMed ID: 9865386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine.
    Sluis-Cremer N; Dmitrienko GI; Balzarini J; Camarasa MJ; Parniak MA
    Biochemistry; 2000 Feb; 39(6):1427-33. PubMed ID: 10684624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication.
    Nguyen Van Nhien A; Tomassi C; Len C; Marco-Contelles JL; Balzarini J; Pannecouque C; De Clercq E; Postel D
    J Med Chem; 2005 Jun; 48(13):4276-84. PubMed ID: 15974581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond.
    Velázquez S; Lobatón E; De Clercq E; Koontz DL; Mellors JW; Balzarini J; Camarasa MJ
    J Med Chem; 2004 Jun; 47(13):3418-26. PubMed ID: 15189038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and anti-HIV-1 activity of novel TSAO-T derivatives modified at the 2'- and 5'-positions of the sugar moiety.
    Ingate S; Pérez-Pérez MJ; De Clercq E; Balzarini J; Camarasa MJ
    Antiviral Res; 1995 Jun; 27(3):281-99. PubMed ID: 8540750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TSAO-T analogues bearing amino acids at position N-3 of thymine: synthesis and anti-human immunodeficiency virus activity.
    Chamorro C; De Clercq E; Balzarini J; Camarasa MJ; San-Félix A
    Antivir Chem Chemother; 2000 Jan; 11(1):61-9. PubMed ID: 10693655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
    Pelemans H; Aertsen A; Van Laethem K; Vandamme AM; De Clercq E; Pérez-Pérez MJ; San-Félix A; Velázquez S; Camarasa MJ; Balzarini J
    Virology; 2001 Feb; 280(1):97-106. PubMed ID: 11162823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel concepts in the treatment of human immunodeficiency virus type 1 (HIV-1) infections by HIV-1-specific reverse transcriptase inhibitors.
    Balzarini J
    Verh K Acad Geneeskd Belg; 1995; 57(6):575-600. PubMed ID: 8686372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Second generation" of TSAO compounds directed against HIV-1 TSAO-resistant strains.
    Lobatón E; Velázquez S; Pérez-Pérez MJ; Jimeno ML; San-Félix A; De Clercq E; Balzarini J; Camarasa MJ
    Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):707-10. PubMed ID: 11563097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.